DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 208 filers reported holding DENALI THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $795,726 | +34.9% | 34,269 | +19.2% | 0.03% | +65.0% |
| Q1 2024 | $590,073 | +14.3% | 28,756 | +19.5% | 0.02% | -20.0% |
| Q4 2023 | $516,264 | +1.6% | 24,057 | -2.3% | 0.02% | -3.8% |
| Q3 2023 | $508,096 | -36.4% | 24,629 | -9.0% | 0.03% | -33.3% |
| Q2 2023 | $798,511 | +29.3% | 27,059 | +1.0% | 0.04% | +25.8% |
| Q1 2023 | $617,449 | -11.6% | 26,799 | +6.7% | 0.03% | -16.2% |
| Q4 2022 | $698,476 | +11.6% | 25,116 | +23.1% | 0.04% | +5.7% |
| Q3 2022 | $626,000 | +59.3% | 20,397 | +52.8% | 0.04% | +75.0% |
| Q2 2022 | $393,000 | +8.3% | 13,350 | +18.2% | 0.02% | +17.6% |
| Q1 2022 | $363,000 | -15.6% | 11,296 | +17.2% | 0.02% | -10.5% |
| Q4 2021 | $430,000 | -8.5% | 9,638 | +3.5% | 0.02% | -9.5% |
| Q3 2021 | $470,000 | – | 9,312 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |